Of note, an ongoing Phase 1 clinical trial is testing the safety and tolerability of RU486 in combination with nab-PX for advanced ER-negative, PR-negative and HER2-negative breast cancer (NCT01493310). Here, ERBB2 is linked to breast carcinoma.